日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

PANTAX: a phase Ib clinical trial of the efflux pump inhibitor SCO-101 in combination with gemcitabine and nab-paclitaxel in non-resectable or metastatic pancreatic cancer

PANTAX:一项针对不可切除或转移性胰腺癌的Ib期临床试验,研究外排泵抑制剂SCO-101联合吉西他滨和白蛋白紫杉醇的疗效。

Shim, Susy; Reinacher-Schick, Anke; Kraeft, Anna-Lena; Per Pfeiffer; Tarpgaard, Line Schmidt; Ettrich, Thomas Jens; Kestler, Angelika; Christensen, Signe; Jandu, Haatisha; Nawabi, Mubeen; Roest, Nicklas Lindland; Damstrup, Lars; Vestlev, Peter Michael; Brünner, Nils; Stenvang, Jan; Ladekarl, Morten

Antibody-drug conjugates (ADCs) targeting trophoblast cell surface antigen 2 (Trop-2) and precision treatment of breast cancer

靶向滋养层细胞表面抗原2 (Trop-2) 的抗体药物偶联物 (ADC) 和乳腺癌的精准治疗

Stenvang, Jan; Vestlev, Peter Michael; Jensen, Benny Vittrup; Pfeiffer, Per

Four phase 1 trials to evaluate the safety and pharmacokinetic profile of single and repeated dosing of SCO-101 in adult male and female volunteers

四项 1 期试验旨在评估 SCO-101 在成年男性和女性志愿者中单次和重复给药的安全性和药代动力学特征。

Bergmann, Troels K; Stage, Tore B; Stenvang, Jan; Christophersen, Palle; Jacobsen, Thomas A; Roest, Nicklas L; Vestlev, Peter M; Brünner, Nils